The effect of subcutaneous semaglutide injection on blood pressure: a systematic review and meta-analysis of randomized controlled trials.
Semaglutide consistently lowers blood pressure alongside weight loss, adding cardiovascular benefit for people with obesity.
A meta-analysis pooled seven randomized trials evaluating blood-pressure effects of subcutaneous semaglutide. The consistent systolic reduction strengthens cardiometabolic benefit evidence, while the smaller diastolic effect was less robust.
What the study was
- Study design
- Systematic review and meta-analysis of randomized controlled trials
- Population
- Participants receiving subcutaneous semaglutide in seven randomized trials
- Sample size
- 20000
- Category
- Prevention
- Maturity
- Validated
- Journal
- Diabetes research and clinical practice
Why it surfaced
Large randomized evidence provides a reliable cardiometabolic effect estimate, although the outcome is intermediate rather than a clinical event.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.